Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
MMB · 2 trials · 7 indications
The percentage of subjects who became transfusion independent for ≥ 12 weeks at any time on study. A subject was considered transfusion independent on study if no RBC transfusion occurred in any 12-week period during the 24-week treatment period.
| Arm | Type | Description |
|---|---|---|
| Cohort 1: Study GS-US-352-0101 | OTHER | Participants will continue to receive the same dosage regimen as in the previous MMB study GS-US-352-0101 until MMB receives regulatory approval and is commercially available, or development of the product ceases. |
| Cohort 2: Study GS-US-352-1214 | OTHER | Participants will continue to receive the same dosage regimen as in the previous MMB study GS-US-352-1214 until MMB receives regulatory approval and is commercially available, or development of the product ceases. |
| Cohort 3: Study GS-US-352-1154 | OTHER | Participants will continue to receive the same dosage regimen as in the previous MMB study GS-US-352-1154 until MMB receives regulatory approval and is commercially available, or development of the product ceases.. |
| Cohort 4: Study SRA-MMB-301 | OTHER | Participants will continue to receive the same dosage regimen as in the previous MMB study SRA-MMB-301 until MMB receives regulatory approval and is commercially available, or development of the product ceases. |
| Momelotinib | EXPERIMENTAL | MMB for 24 weeks (± 7 days) |
| Name | Type | Description |
|---|---|---|
| MMB | DRUG | Tablet(s) administered orally once daily |
Key Inclusion Criteria: * Currently enrolled in Studies GS-US-352-0101, GS-US-352-1214, GS-US-352-1154, or SRA-MMB-301 * Able to comprehend and willing to sign the informed consent form Key Exclusion Criteria: * Known hypersensitivity to MMB, its metabolites, or formulation excipients NOTE: Othe...
MMB is an investigational small molecule being developed for Primary Myelofibrosis (PMF) and related myeloproliferative neoplasms, including post-polycythemia vera and post-essential thrombocythemia myelofibrosis. It is studied in transfusion-dependent adults with these conditions. MMB is currently in Phase 2 clinical development and is not approved by regulatory authorities.
MMB is being developed by GSK plc, a global biopharmaceutical company listed on the stock exchange under the ticker GSK. GSK is conducting clinical trials to evaluate MMB in patients with myelofibrosis and related neoplasms.
MMB is in Phase 2 clinical development. Two Phase 2 trials have been conducted: one completed study and one active but not recruiting extended access study. MMB is an investigational agent and has not received regulatory approval for any indication.
MMB has been studied in two clinical trials. NCT02515630 is a completed Phase 2 study in transfusion-dependent adults with primary myelofibrosis or post-PV/ET myelofibrosis. NCT03441113 is an active extended access study enrolling 237 adults with myelofibrosis and related neoplasms across multiple countries.
Yes, MMB is also known as momelotinib. Clinical trial records refer to the drug as momelotinib, and MMB is used as a shorthand identifier. Both names refer to the same investigational small molecule being developed by GSK for myelofibrosis.